Abstract:Nattokinase (NK), known as a potent fibrinolytic and antithrombotic agent, has been shown to have antiatherosclerotic and lipid-lowering effects. However, data on human clinical studies are limited. In this clinical study involving 1,062 participants, our objective was to examine the efficacy of NK in atherosclerosis and hyperlipidemia and safety at the dose of 10,800 FU/day after 12 months of oral administration. Various factors, including lower doses that influence NK pharmacological actions, were also investigated. We found that NK at a dose of 10,800 FU/day effectively managed the progression of atherosclerosis and hyperlipidemia with a significant improvement in the lipid profile. A significant reduction in the thickness of the carotid artery intima-media and the size of the carotid plaque was observed. The improvement rates ranged from 66.5 to 95.4%. NK was found to be ineffective in lowering lipids and suppressing atherosclerosis progression at a dose of 3,600 FU/day. The lipid-lowering effect of NK was more prominent in subjects who smoked, drank alcohol, and subjects with higher BMI. Regular exercise further improved the effects of NK. Co-administration of vitamin K2 and aspirin with NK produced a synergetic effect. No noticeable adverse effects associated with the use of NK were recorded. In conclusion, our data demonstrate that atherosclerosis progression and hyperlipidemia can be effectively managed with NK at a dose of 10,800 FU/day. The lower dose of 3,600 FU per day is ineffective. The dose of 10,800 FU/day is safe and well tolerated. Some lifestyle factors and the coadministration of vitamin K2 and aspirin lead to improved outcomes in the use of NK. Our findings provide clinical evidence on the effective dose of NK in the management of cardiovascular disease and challenge the recommended dose of 2,000 FU per day.

Preserving the Activity of Attenuating Atherosclerosis of Nattokinase in Gastrointestinal System by NK/SA/CS Microcapsules

Layer-by-layer self-assembly embedding of nattokinase in chitosan/γ-polyglutamic acid: Preparation, fibrinolytic activity, stability, and in vitro digestion study

Chitosan/Casein Based Microparticles With A Bilayer Shell-Core Structure For Oral Delivery Of Nattokinase

Preparation and property studies of enteric-soluble oral nattokinase microcapsules with halloysite nanotubes

Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants

Study on Molecular Mechanisms of Nattokinase in Pharmacological Action Based on Label‐free Liquid Chromatography–tandem Mass Spectrometry

Nattokinase attenuates endothelial inflammation through the activation of SRF and THBS1

Study on the Transport and Internalisation Mechanism of Dietary Supplement Nattokinase in the Small Intestine Using Animal and Caco-2 Cell Monolayer Models.

A Nattokinase‐Loaded Nanozyme for Alleviating Acute Myocardial Infarction via Thrombolysis and Antioxidation

Nattokinase Attenuated Excitatory Amino Acids and Cytokines Release and Restored Cerebral Blood Flow in a Thrombolytic Focal Cerebral Ischemic Rat Model

Research Progress on Functional Vectors for Nattokinase Delivery

Biomimetic nanoparticles: U937 cell membranes based core–shell nanosystems for targeted atherosclerosis therapy

Lipid-lowering, antihypertensive, and antithrombotic effects of nattokinase combined with red yeast rice in patients with stable coronary artery disease: a randomized, double-blinded, placebo-controlled trial

Thrombolytic Activity of Nattokinase Produced by Bacillus Subtilis Natto LNUB236

Nattokinase's Neuroprotective Mechanisms in Ischemic Stroke: Targeting Inflammation, Oxidative Stress, and Coagulation

Long-term and Liver-Selected Ginsenoside C-K Nanoparticles Retard NAFLD Progression by Restoring Lipid Homeostasis.

Nattokinase as an adjuvant therapeutic strategy for non-communicable diseases: a review of fibrinolytic, antithrombotic, anti-inflammatory, and antioxidant effects

Synthesis of sustained release/controlled release nanoparticles carrying nattokinase and their application in thrombolysis.

β-Cyclodextrin and Hyaluronic Acid-Modified Targeted Nanodelivery System for Atherosclerosis Prevention

Long-term and liver-selected ginsenoside C–K nanoparticles retards NAFLD progression by restoring lipid homeostasis

Nattokinase: Insights into Biological Activity, Therapeutic Applications, and the Influence of Microbial Fermentation